|
|
|
ZSPH - ZS Pharma, Inc.
ZS Pharma, Inc. (ZSPH) was a US-based biopharmaceutical company that focused on developing and commercializing novel treatments for kidney and cardiovascular diseases. The company's lead product candidate, ZS-9, was a treatment for hyperkalemia, a condition characterized by abnormally high levels of potassium in the blood.
ZS Pharma was founded in 2008 and was headquartered in San Mateo, California. In 2015, the company was acquired by AstraZeneca plc, a global pharmaceutical company, for $2.7 billion. Following the acquisition, ZS Pharma became a wholly-owned subsidiary of AstraZeneca.
As of February 2023, ZS Pharma, Inc. no longer exists as a standalone company, and its operations have been integrated into AstraZeneca's global research and development pipeline. The ZS-9 product is now marketed under the brand name Lokelma and is used to treat hyperkalemia in adult patients. AstraZeneca continues to invest in research and development efforts aimed at developing new treatments for kidney and cardiovascular diseases.
|
|
|
|
|
